PMM1

Across TCGA pan-cancer cohorts, PMM1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PMM1 data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PMM1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PMM1 expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LUAD are the cancer types where PMM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.613	0.899	.016	8	view →
PDAC	OS	Median	All	0.691	0.950	.010	8	view →
LUAD	DFS	Quartile	All	0.799	0.976	.003	5	view →
GBM	OS	Tertile	All	0.208	0.507	.036	4	view →
LSCC	DFS	Tertile	III,IV	0.588	1.000	.016	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PMM1–CCRCC (DFS)

Open the CCRCC breakdown →